Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
For full-year 2024 revenue, the company is providing guidance of approximately $54 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -0.53% |
|
-1.56% | -5.03% |
14/05 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
13/05 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-5.03% | 32.84M | |
+25.78% | 89.17B | |
-23.45% | 75.87B | |
+2.61% | 27.41B | |
-8.56% | 17.52B | |
+0.78% | 17.04B | |
+0.30% | 15.36B | |
+78.55% | 13.18B | |
+77.76% | 13.67B | |
-25.79% | 12.83B |